Dyslipidemia Clinical Trial
Official title:
Assessment Of Statin Treatment Compliance In Dyslipidemia Patients: An Observational Study
| NCT number | NCT00673660 |
| Other study ID # | A2581156 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | October 2007 |
| Est. completion date | October 2009 |
| Verified date | February 2021 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The purpose of the study is to show the compliance rates of the patients to statin treatment and the reasons of non-compliance.
| Status | Completed |
| Enrollment | 375 |
| Est. completion date | October 2009 |
| Est. primary completion date | October 2009 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients diagnosed with dyslipidemia and taking or planning to take statin treatment. - Patients living in the same city of the study center. o Patients aged 18 years and over. Exclusion Criteria: - Patients with severe systemic disease - Patients with alcohol and drug addiction and/or mental disease - Patients nursing or pregnant, or planning to get pregnant during the study |
| Country | Name | City | State |
|---|---|---|---|
| Turkey | Pfizer Investigational Site | Bolu | |
| Turkey | Pfizer Investigational Site | Haseki/Istanbul | |
| Turkey | Pfizer Investigational Site | Istanbul | |
| Turkey | Pfizer Investigational Site | Istanbul | |
| Turkey | Pfizer Investigational Site | Mecidiyekoy | Istanbul |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
Turkey,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of Participants Who Were Compliant With Statin Treatment | The physician asked participants about their compliance with medication use, which was defined as not skipping or forgetting dosing or not delaying the dosing time at least 80 percent (%) of the days in which the medication was used. | Month 12 | |
| Secondary | Available Lipid Profiles of Compliant and Non-compliant Participants | Available laboratory measurements of participants were recorded in CRFs. | Month 12 | |
| Secondary | Number of Participants With Reasons of Compliance to Statin Treatment | Compliance with medication use defined as not skipping or forgeting dosing or not delaying the dosing time at least 80 percent (%) of the days in which the medication was used. Participants were called for a final visit . Compliance with drug dosage was recorded. | Month 12 | |
| Secondary | Number of Participants With Reasons of Non-compliance to Statin Treatment | Participants were called for a final visit and reasons for non-compliance were recorded. | Month 12 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
| Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
| Recruiting |
NCT02837367 -
Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People
|
N/A | |
| Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
| Active, not recruiting |
NCT02600338 -
Meta-analyses of the Effect of Legumes on Blood Pressure
|
N/A | |
| Completed |
NCT02163044 -
The Hellenic Postprandial Lipemia Study (HPLS)
|
||
| Recruiting |
NCT01972113 -
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
|
N/A | |
| Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
| Completed |
NCT01764295 -
Clinical Study for Patients With Hypertension Associated With Dyslipidemia
|
Phase 3 | |
| Completed |
NCT01990391 -
Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities
|
N/A | |
| Completed |
NCT01531062 -
Effect of Nigella Sativa on Lipid Profiles in Elderly
|
Phase 2 | |
| Terminated |
NCT01414166 -
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
|
Phase 3 | |
| Recruiting |
NCT01670968 -
HIV Reverse Cholesterol Transport Study
|
||
| Completed |
NCT00977288 -
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
|
Phase 2 | |
| Withdrawn |
NCT00664287 -
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
|
Phase 3 | |
| Completed |
NCT01285544 -
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
|
Phase 4 | |
| Completed |
NCT00768274 -
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
|
Phase 1/Phase 2 | |
| Completed |
NCT01483235 -
Reduced Cardiac Rehabilitation Program
|
N/A | |
| Completed |
NCT00300430 -
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
|
Phase 3 | |
| Completed |
NCT00309777 -
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
|
Phase 3 |